SurModics (SRDX) Was Downgraded to a Hold Rating at Barrington
Sidoti & Co. Downgrades Surmodics to Neutral, Announces $43 Price Target
Sidoti & Co. : The Surmodics (SRDX.US) rating was downgraded from buying to neutral, and the target price was $43.00.
Surmodics Analyst Ratings
SurModics (SRDX) Was Downgraded to a Hold Rating at Needham
SurModics (SRDX) Gets a Buy From Lake Street
Analysts Are Bullish on These Healthcare Stocks: Assertio Therapeutics (ASRT), SurModics (SRDX)
Barrington Research: Maintaining the Surmodics (SRDX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $71.00 to $71.00.
Surmodics Analyst Ratings
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
Needham: Maintaining the Surmodics (SRDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $47.00 to $43.00.
Surmodics Analyst Ratings
Needham Maintains Buy on Surmodics, Lowers Price Target to $43
SurModics Outperforms With Raised Guidance and Strong Product Momentum: Buy Rating Reaffirmed
Analysts Offer Insights on Healthcare Companies: SurModics (SRDX) and Pfizer (PFE)
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
Needham: Reiterates Surmodics (SRDX.US) rating and adjusted from buy to buy rating, target price is $47.00.
Surmodics Analyst Ratings
Needham Reiterates Buy on Surmodics, Maintains $47 Price Target
No Data